Viridian Therapeutics (VRDN) Goldman Sachs 46th Annual Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Goldman Sachs 46th Annual Global Healthcare Conference summary
8 Jul, 2026Portfolio progress and clinical milestones
Advancing portfolio with positive phase 3 data in both active and chronic patient populations; BLA filing targeted for second half of the year, pending final THRIVE-2 chronic study follow-up data.
Long-term follow-up data for the active study showed durable response; breakthrough therapy designation received, increasing odds for priority review and potentially accelerating launch timing.
Subcutaneous (sub-Q) program in phase 3 (Reveal 1 and 2) is on track, with top-line readout expected in the first half of next year.
FCRN portfolio progressing, with healthy volunteer data expected in Q3 and IND filing for half-life extended version by year-end.
Safety, efficacy, and differentiation
52-week safety data for the active study showed a favorable profile, with most adverse events mild and resolved.
Data indicate lower hearing impairment rates compared to Tepezza, with most hearing-related events being mild and reversible.
Five infusions and lower drug dose (70% less than Tepezza) offer a differentiated treatment profile, potentially increasing patient access.
Durability data show 70% of patients maintained proptosis response at week 52, compared to 53% in Tepezza's label.
Market landscape and commercial strategy
U.S. commercial launch preparations are advanced, with a full senior team and launch plans in place; priority review could accelerate launch.
Market remains robust, with over 400 patients enrolled in trials last year and strong demand from both U.S. and international sites.
Sub-Q formulation expected to drive further market penetration, offering at-home administration via auto-injector.
Commercial strategy targets 2,000 core prescribers in the U.S., leveraging existing disease awareness efforts by competitors.
Latest events from Viridian Therapeutics
- LUMVOA gains launch traction as subQ TED and Q8-week FcRn programs advance.VRDN
Jefferies Global Healthcare Conference - Lumvoa launch gains traction as TED and autoimmune pipeline milestones advance.VRDN
Corporate presentation - Phase I data support Q8W VRDN-008, with MG registrational development planned for mid-2027.VRDN
Study update - Lumvoa generated $24.7M in its first quarter as elegrobart advanced toward a Q1 2027 BLA.VRDN
Q3 2026 - Strong Lumvoa IV launch and pipeline progress position for TED market expansion and leadership.VRDN
Wells Fargo 21st Annual Healthcare Conference - FDA approval and strong cash reserves drive commercial and pipeline momentum in TED.VRDN
Q2 2026 - Lumvoa and elegrobart drive innovation in TED, with a robust pipeline for autoimmune expansion.VRDN
Company presentation - FDA approves Lumvoa for all forms of TED, offering rapid, durable relief and immediate access.VRDN
FDA announcement - Significant efficacy and safety in chronic TED support a 2027 BLA for a subcutaneous autoinjector.VRDN
Study result